06/12/2005 - 21:00

QPSX Ltd30-Nov-05

06/12/2005 - 21:00

Bookmark

Save articles for future reference.

CSIRO, through its Division of Molecular and Health Technologies and Offspring Ventures, a subsidiary of QPSX Ltd, have entered into an arrangement to commercialize some of the Division’s ecdysone receptor technology.

To read our articles you will need to either login or subscribe.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options